RespireRx Pharmaceuticals Inc (fka RSPI)

[meixatech]

Based on this, it is likely that Cortex has deals being offered, which if the content were publicly known, the pps would be much higher than it is now. I would be willing to bet (hmmmm, I think I am) that even if there is an unlikely FDA turn down of lifting dosage for CX717, Cortex will still get a sweet deal (just not as sweet if approved).